Medical treatments: In association or alone, their role and their future perspectives. Novel molecular-targeted therapy for hepatocellular carcinoma

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 17, Issue 4, 2010, Pages 413-419

  Tanaka, Shinji ^a   Arii, Shigeki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Aurora kinase B; Molecular targeted therapy; Network analysis; Oncogene addiction

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; AURORA B KINASE; AURORA KINASE INHIBITOR; BARASERTIB; AURORA KINASE; DNA; PROTEIN SERINE THREONINE KINASE;

APOPTOSIS; AURKB GENE; CANCER INHIBITION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TUMOR; MALIGNANT NEOPLASTIC DISEASE; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; POLYPLOIDY; PROGNOSIS; REVIEW; SURVIVAL RATE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; TREATMENT OUTCOME; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROTEIN-SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 79952111011     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-009-0238-8     Document Type: Review

References (23)

1. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6:674-87. (Pubitemid 44286000)
2. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224-9.
3. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5(3):215-9. (Pubitemid 38402113)
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
5. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312-27.
6. Tanaka S, Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009;100:1-8.
7. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006;3:448-57. (Pubitemid 44203817)
8. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136:823-37.
9. Tanaka S, Noguchi N, Ochiai T, Kudo A, Nakamura N, Ito K, et al. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting Milan criteria: rationale for partial hepatectomy as first strategy. J Am Coll Surg. 2007;204:1-6. (Pubitemid 44960045)
10. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008;95:611-9.
11. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2009 (in press).
12. Sherman M. Recurrence of hepatocellular carcinoma. N Engl J Med. 2008;359:2045-7.
13. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med. 1996;334:693-9. (Pubitemid 26079803)
14. Bader GD, Donaldson I, Wolting C, Ouellette BFF, Hogue PawsonT, WV C. BIND - the biomolecular interaction network database. Nucleic Acids Res. 2001;29:242-5. (Pubitemid 32054459)
15. Batagelj V, Mrvar A. Graph drawing software: Pajek-analysis and visualization of large networks. In: Junger M, Mutzel P, editors. Mathematics and visualization. Berlin: Springer; 2004. p. 77-103.
16. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Curr Opin Genet Dev. 2007;17:60-5. (Pubitemid 46109297)
17. Inazawa J, Inoue J, Imoto I. Comparative genomic hybridization (CGH)-arrays pave the way for identification of novel cancerrelated genes. Cancer Sci. 2004;95:559-63. (Pubitemid 39089635)
18. Keen N, Taylor S. Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 2004;4:927-36. (Pubitemid 39626216)
19. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol. 2007;8:798-812. (Pubitemid 47462135)
20. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001;1:46-54. (Pubitemid 33741880)
21. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441-54.
22. Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, et al. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology. 2007;46:1119-30. (Pubitemid 350144776)
23. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137:835-48.